Marathon Pharmaceuticals LLC

Emalex Biosciences Inc. significantly expanded on its previous capacity to fund the upcoming Phase III clinical trial of ecopipam in Tourette’s syndrome with a $250m series D financing barely a year

The flow of venture capital into biopharmaceutical companies has been astonishing – breaking the prior record by a wide margin in 2020 – and, so far, 2021 looks like it is on track to leave a big gap

PTC Therapeutics, Inc. CEO Stuart Peltz told Scrip that with $1.1bn in the bank the company has never been better capitalized to fund its pipeline of rare disease drug candidates. And with royaltie

Jeffrey Aronin, the former CEO of Marathon Pharmaceuticals LLC , has been building a portfolio of new drug companies under the Paragon Biosciences LLC umbrella over the last two years, with a focus